Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis
- PMID: 23326517
- PMCID: PMC3543264
- DOI: 10.1371/journal.pone.0053830
Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis
Abstract
Genetic factors explain a majority of risk variance for age-related macular degeneration (AMD). While genome-wide association studies (GWAS) for late AMD implicate genes in complement, inflammatory and lipid pathways, the genetic architecture of early AMD has been relatively under studied. We conducted a GWAS meta-analysis of early AMD, including 4,089 individuals with prevalent signs of early AMD (soft drusen and/or retinal pigment epithelial changes) and 20,453 individuals without these signs. For various published late AMD risk loci, we also compared effect sizes between early and late AMD using an additional 484 individuals with prevalent late AMD. GWAS meta-analysis confirmed previously reported association of variants at the complement factor H (CFH) (peak P = 1.5×10(-31)) and age-related maculopathy susceptibility 2 (ARMS2) (P = 4.3×10(-24)) loci, and suggested Apolipoprotein E (ApoE) polymorphisms (rs2075650; P = 1.1×10(-6)) associated with early AMD. Other possible loci that did not reach GWAS significance included variants in the zinc finger protein gene GLI3 (rs2049622; P = 8.9×10(-6)) and upstream of GLI2 (rs6721654; P = 6.5×10(-6)), encoding retinal Sonic hedgehog signalling regulators, and in the tyrosinase (TYR) gene (rs621313; P = 3.5×10(-6)), involved in melanin biosynthesis. For a range of published, late AMD risk loci, estimated effect sizes were significantly lower for early than late AMD. This study confirms the involvement of multiple established AMD risk variants in early AMD, but suggests weaker genetic effects on the risk of early AMD relative to late AMD. Several biological processes were suggested to be potentially specific for early AMD, including pathways regulating RPE cell melanin content and signalling pathways potentially involved in retinal regeneration, generating hypotheses for further investigation.
Conflict of interest statement
Figures



Similar articles
-
A Deep Phenotype Association Study Reveals Specific Phenotype Associations with Genetic Variants in Age-related Macular Degeneration: Age-Related Eye Disease Study 2 (AREDS2) Report No. 14.Ophthalmology. 2018 Apr;125(4):559-568. doi: 10.1016/j.ophtha.2017.09.023. Epub 2017 Oct 31. Ophthalmology. 2018. PMID: 29096998 Free PMC article. Clinical Trial.
-
Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease.BMC Med Genomics. 2020 Aug 26;13(1):120. doi: 10.1186/s12920-020-00760-7. BMC Med Genomics. 2020. PMID: 32843070 Free PMC article.
-
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18.Ophthalmology. 2019 Nov;126(11):1541-1548. doi: 10.1016/j.ophtha.2019.06.004. Epub 2019 Jun 12. Ophthalmology. 2019. PMID: 31358387 Free PMC article. Clinical Trial.
-
Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.Acta Ophthalmol. 2018 Mar;96(2):e105-e110. doi: 10.1111/aos.13494. Epub 2017 Jun 8. Acta Ophthalmol. 2018. PMID: 28593728 Review.
-
Genomic aspects of age-related macular degeneration.Biochem Biophys Res Commun. 2014 Sep 19;452(2):263-75. doi: 10.1016/j.bbrc.2014.08.013. Epub 2014 Aug 8. Biochem Biophys Res Commun. 2014. PMID: 25111812 Review.
Cited by
-
Differences in the Genetic Susceptibility to Age-Related Macular Degeneration Clinical Subtypes.Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4290-9. doi: 10.1167/iovs.15-16533. Invest Ophthalmol Vis Sci. 2015. PMID: 26176866 Free PMC article.
-
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.Blood Cancer J. 2023 Feb 27;13(1):31. doi: 10.1038/s41408-023-00802-0. Blood Cancer J. 2023. PMID: 36849497 Free PMC article.
-
Age-related macular degeneration: genetics and biology coming together.Annu Rev Genomics Hum Genet. 2014;15:151-71. doi: 10.1146/annurev-genom-090413-025610. Epub 2014 Apr 16. Annu Rev Genomics Hum Genet. 2014. PMID: 24773320 Free PMC article. Review.
-
Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration.Exp Eye Res. 2016 Apr;145:269-277. doi: 10.1016/j.exer.2016.01.018. Epub 2016 Feb 13. Exp Eye Res. 2016. PMID: 26854823 Free PMC article.
-
Nutritional and Lifestyle Interventions for Age-Related Macular Degeneration: A Review.Oxid Med Cell Longev. 2017;2017:6469138. doi: 10.1155/2017/6469138. Epub 2017 Jan 5. Oxid Med Cell Longev. 2017. PMID: 28154734 Free PMC article. Review.
References
-
- Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379: 1728–1738. - PubMed
-
- Sallo FB, Peto T, Leung I, Xing W, Bunce C, et al. (2009) The International Classification system and the progression of age-related macular degeneration. Curr Eye Res 34: 238–240. - PubMed
-
- Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K (2011) Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. - PubMed
-
- Abdelsalam A, Del Priore L, Zarbin MA (1999) Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 44: 1–29. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- UL1TR000124/TR/NCATS NIH HHS/United States
- N01 AG012100/AG/NIA NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- R01 AG020098/AG/NIA NIH HHS/United States
- HL080295/HL/NHLBI NIH HHS/United States
- N01-HC-85084/HC/NHLBI NIH HHS/United States
- R01HL086694/HL/NHLBI NIH HHS/United States
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- UL1RR025005/RR/NCRR NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- N01-HC-85085/HC/NHLBI NIH HHS/United States
- R01HL59367/HL/NHLBI NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- R01 AG015928/AG/NIA NIH HHS/United States
- ZIA EY000426/ImNIH/Intramural NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- Z99 EY999999/ImNIH/Intramural NIH HHS/United States
- Z01 EY000426/ImNIH/Intramural NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- ZIA EY000401/ImNIH/Intramural NIH HHS/United States
- R01 HL059367/HL/NHLBI NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- HL105756/HL/NHLBI NIH HHS/United States
- N01 HC015103/HC/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- ZIAEY000401/PHS HHS/United States
- AG-15928/AG/NIA NIH HHS/United States
- R56 AG020098/AG/NIA NIH HHS/United States
- 4584/CRUK_/Cancer Research UK/United Kingdom
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- R01 HL086694/HL/NHLBI NIH HHS/United States
- 085475/B/08/Z/WT_/Wellcome Trust/United Kingdom
- R01 HL087652/HL/NHLBI NIH HHS/United States
- AG-20098/AG/NIA NIH HHS/United States
- ZIA AG007380/ImNIH/Intramural NIH HHS/United States
- HL087652/HL/NHLBI NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- HHSN268200625226C/PHS HHS/United States
- U01 HG004402/HG/NHGRI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- ZIAAG007380/PHS HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- U01HG004402/HG/NHGRI NIH HHS/United States
- AG-027058/AG/NIA NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- N01 HC-55222/HC/NHLBI NIH HHS/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- R01HL087641/HL/NHLBI NIH HHS/United States
- N01 HC055222/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- 090532/WT_/Wellcome Trust/United Kingdom
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- R01 HL080295/HL/NHLBI NIH HHS/United States
- Z01 EY000401/ImNIH/Intramural NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- N01-AG-12100/AG/NIA NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- DK063491/DK/NIDDK NIH HHS/United States
- N01-HC-45133/HC/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01-HC-85239/HC/NHLBI NIH HHS/United States
- AG-023629/AG/NIA NIH HHS/United States
- N01 HC075150/HL/NHLBI NIH HHS/United States
- R01 HL087641/HL/NHLBI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- 085475/08/Z/WT_/Wellcome Trust/United Kingdom
- R01 AG027058/AG/NIA NIH HHS/United States
- N01 HC045133/HC/NHLBI NIH HHS/United States
- N01 HC035129/HC/NHLBI NIH HHS/United States
- R56 AG023629/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous